Form 4: Equillium Officer Sells Shares, Gains Options

Equillium's Principal Accounting Officer, Tom Penny, reported the sale of common stock and the acquisition of new employee stock options.

Summary

• Tom Penny, Principal Accounting Officer of Equillium, Inc. [EQ], reported transactions involving the company's securities.
• Penny sold 6,533 shares of common stock at a price of $1.29 per share on January 8, 2026.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on October 10, 2025.
• Penny acquired 450,000 employee stock options with an exercise price of $1.31 per share on January 7, 2026.
• The acquired options have a vesting schedule where 25% vest on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments over the subsequent three years.
• The employee stock options have an expiration date of January 6, 2036.

Sentiment

Score: 5

Explanation: The filing reports standard insider transactions (sale under 10b5-1 plan and option grant) which are generally neutral in sentiment unless the scale or context suggests otherwise. The option grant balances the share sale.

Positives

• Acquisition of 450,000 employee stock options, aligning management's long-term incentives with shareholder value.
• The options have a long expiration date of January 6, 2036, providing a substantial window for potential value realization.

Negatives

• Sale of 6,533 shares of common stock by a Principal Accounting Officer, which could be perceived as a reduction in direct equity exposure.

Future Outlook

The acquisition of significant employee stock options suggests a long-term commitment and alignment of the Principal Accounting Officer with the company's future performance, contingent on the vesting schedule.

Industry Context

This Form 4 filing details routine insider trading activity, specifically the sale of shares under a pre-arranged trading plan and the grant of new stock options, which are common compensation practices in the biotechnology and pharmaceutical industries to incentivize executives.

Management Changes

Stakeholder Impact

• Shareholders: The sale of shares by an officer could be viewed with slight caution, though mitigated by the 10b5-1 plan. The grant of options aligns management's interests with long-term shareholder value.
• Employees: The grant of employee stock options is a common incentive mechanism for key personnel.

Next Steps

• Vesting of 25% of the 450,000 employee stock options on the first anniversary of the vesting commencement date.
• Subsequent monthly vesting of the remaining employee stock options over 36 equal installments.

Key Dates

Keywords

Equillium, EQ, Form 4, Insider Transaction, Stock Options, Common Stock, Tom Penny, Principal Accounting Officer, 10b5-1 Plan